Asset Details
Do you wish to reserve the book?
Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis
Do you wish to request the book?
Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis
2012
Overview
In this 12-week, phase 2 trial, an anti–interleukin-17–receptor antibody was effective in treating moderate-to-severe psoriasis. Adverse events included neutropenia. Larger trials of longer duration are needed to assess the risk of infections.
Psoriasis is a chronic T-cell–mediated autoimmune disease
1
that affects 2 to 3% of the U.S. population
2
,
3
and 0.6 to 6.5% of the European population.
4
Emerging data identify a subset of helper T cells, Th17, that preferentially produce interleukin-17 and play a major role in orchestrating inflammation in psoriasis.
5
–
7
Levels of interleukin-17 are elevated in the lesional skin and blood of patients with psoriasis
5
,
8
–
10
and correlate with disease severity.
11
The interleukin-17 cytokine family consists of six cytokines (interleukins 17A to 17F) and five receptors (interleukins 17RA to 17RE).
12
The interleukin 17A, 17F, and 17A/F heterodimer ligands share . . .
Publisher
Massachusetts Medical Society
Subject
/ Antibodies, Monoclonal - administration & dosage
/ Antibodies, Monoclonal - adverse effects
/ Antibodies, Monoclonal - therapeutic use
/ Biological and medical sciences
/ Dose-Response Relationship, Drug
/ Erythema
/ Female
/ Humans
/ Male
/ Patients
/ Psoriasis. Parapsoriasis. Lichen
/ Receptors, Interleukin-17 - antagonists & inhibitors
